Biogen (BIIB) weekly option implied volatility elevated into Q1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- eToro to acquire TradeZero for up to $231M to expand in US
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Piper Jaffray Remains Bullish on Biogen (BIIB) Following 1Q
April 24, 2018 8:48 AM EDTPiper Jaffray reiterated an Overweight rating and $407.00 price target on Biogen (NASDAQ: BIIB) following the company's 1Q earnings report. BIIB posted total revenue of $3,131M, missing consensus $3,152M but beating Piper Jaffray's $3,080M estimate. Non-GAAP EPS of $6.05 easily beat consensus $5.93.
BIIB's anti-CD20... More
Biogen (BIIB) Tops Q1 EPS by 13c, Miss on Revenues
April 24, 2018 7:00 AM EDTBiogen (NASDAQ: BIIB) reported Q1 EPS of $6.05, $0.13 better than the analyst estimate of $5.92. Revenue for the quarter came in at $3.1 billion versus the consensus estimate of $3.15 billion.
Total revenues of $3.1 billion, an 11% increase versus the prior year or a 15% increase excluding hemophilia... More